Lead
RFK Jr.’s senior vaccine adviser, Milhoan, publicly questioned whether routine polio immunization remains necessary and mused about the consequences if vaccination were widely abandoned. His remarks, made this month, prompted immediate condemnation from medical leaders who warned that falling coverage would revive paralysis and fatalities once kept at bay. The exchange intensified an ongoing dispute over federal vaccine guidance after recent changes to CDC policy, and comes as 27 states plus Washington, D.C. have said they will not adopt the new CDC recommendations. The American Academy of Pediatrics released a 2026 immunization schedule positioned as an alternative to the CDC’s updated guidance.
Key Takeaways
- Milhoan, a top adviser to RFK Jr., publicly questioned the necessity of the polio vaccine and asked what would happen if herd immunity were removed.
- AMA Trustee Sandra Adamson Fryhofer called his remarks “a dangerous step backward,” warning that polio has no cure and that reduced vaccination leads to paralysis and death.
- A KFF policy brief reports 27 states and Washington, D.C. have announced they will not follow the CDC’s new vaccine guidance.
- The AAP published a 2026 childhood and adolescent vaccine schedule and said 12 medical organizations, including the AMA, endorse it as an alternative.
- AAP President Andrew Racine said the academy’s recommendations remain rooted in science and aim to protect infants, children and adolescents.
- Shifts away from population-focused vaccine policy toward individual autonomy are being framed by some advocates as a philosophical change with major public-health implications.
Background
For decades, U.S. vaccine policy has balanced individual clinical decision-making with population-level strategies aimed at maintaining herd immunity to prevent outbreaks. Advisory bodies such as the Advisory Committee on Immunization Practices (ACIP) historically provided technical guidance to the Centers for Disease Control and Prevention (CDC), which informs federal recommendations. In recent weeks, RFK Jr.’s appointees have revised CDC guidance without ACIP consultation, fracturing long-standing advisory norms and prompting concern among many clinicians and public-health officials.
The controversy unfolds against a landscape where vaccine hesitancy and policy variation across states have already complicated routine immunization programs. When vaccination coverage drops, diseases once rare in the U.S., like polio, can resurface with severe outcomes including lifelong paralysis. Medical societies—ranging from the American Medical Association to specialty infectious-disease groups—have emphasized the evidence base supporting routine childhood immunizations as the primary tool to prevent these outcomes.
Main Event
The immediate trigger was a public session in which Milhoan speculated aloud about the effects of removing herd-immunity assumptions from vaccine policy, asking whether the balance would “teeter” in a different direction if fewer people were vaccinated. His framing shifted attention from collective protection to individual choice, a rhetorical pivot that many clinicians view as a reversal of public-health priorities. The comments were widely circulated by news outlets and amplified on social media, accelerating official responses.
Shortly after the remarks, AMA Trustee Sandra Adamson Fryhofer issued a forceful rebuke, stressing that the debate is not hypothetical and that polio remains incurable. She argued that weakening routine immunization recommendations would translate into higher incidence of paralysis and death. Other medical groups echoed the position that population-level recommendations are grounded in decades of epidemiologic evidence designed to prevent resurgence of controlled diseases.
Concurrently, a KFF policy brief documented that 27 states plus Washington, D.C. intend not to follow the CDC’s recent recommendation set, instead relying on previous CDC guidance or state- and organization-specific schedules. The American Academy of Pediatrics then released its 2026 vaccine schedule for children and adolescents, which it presented as consistent with longstanding evidence and as an accessible option for clinicians uncomfortable with the CDC’s revisions.
Analysis & Implications
Re-centering vaccine policy on individual autonomy reduces the emphasis on herd immunity metrics that have historically guided immunization targets. In practical terms, that shift could lower the coverage thresholds needed to prevent transmission for highly contagious diseases. For polio, which can cause irreversible paralysis and death, even modest declines in coverage increase the risk of localized outbreaks that burden both families and health systems.
Policy fragmentation—states, professional societies and federal agencies endorsing different schedules—creates operational challenges for clinicians, schools, and public-health surveillance. Pediatricians may face inconsistent rules for school enrollment and insurance reimbursement, while public-health authorities would find it harder to identify coverage gaps and respond rapidly to outbreaks. Fragmentation also complicates communication to the public about what constitutes a recommended vaccine.
Economically, a rise in vaccine-preventable illness would increase direct medical costs and indirect societal costs such as long-term disability support and lost labor. Politically, the dispute highlights how governance of technical health policy can become entangled with ideological debates over personal liberty and institutional authority, potentially reshaping who sets standards for preventive care.
Comparison & Data
| Recommendation source | Adoption / support | Notes |
|---|---|---|
| CDC (revised guidance) | Federal | Recent overhaul implemented without ACIP consultation |
| AAP (2026 schedule) | Endorsed by 12 organizations including AMA | Presented as science-rooted alternative to CDC revisions |
| State-level adoption | 27 states + DC rejecting CDC changes | Relying on prior CDC guidance or state/organization recommendations |
The table summarizes current alignment: the CDC’s new guidance sits at odds with AAP-endorsed recommendations and the majority of states that have explicitly declined to adopt the federal update. This patchwork raises measurement problems for national vaccine coverage statistics and complicates outbreak-prevention strategies that depend on consistent thresholds. Public-health surveillance will need to track which schedules are in force where, and adjust outbreak models accordingly.
Reactions & Quotes
This is not a theoretical debate—it is a dangerous step backward. Vaccines have saved millions of lives and virtually eliminated devastating diseases like polio in the United States.
Sandra Adamson Fryhofer, AMA Trustee
Fryhofer’s statement framed the issue as a public-health imperative rather than a philosophical question, emphasizing the historical impact of vaccination on polio control.
The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children and adolescents of this country.
Andrew Racine, AAP President
Andrew Racine presented the AAP’s 2026 schedule as a science-based alternative to the CDC revision, noting broad endorsement by other medical groups.
If we take away all of the herd immunity, then does that switch, does that teeter-totter switch in a different direction?
Milhoan, RFK Jr.’s vaccine adviser (public remarks)
Milhoan’s rhetorical question encapsulated the policy pivot toward individual choice that prompted the medical community’s response.
Unconfirmed
- Any claim that polio no longer poses a public-health risk in the U.S. is not supported by current evidence and remains unproven.
- Reports that specific states will adopt identical new schedules immediately after the CDC revision are variable; some states are using prior guidance or organization-issued schedules instead.
Bottom Line
The episode spotlights a substantive shift in how vaccine policy questions are being framed: from population-level prevention toward an emphasis on individual autonomy. Medical leaders warn that this reframing risks undermining decades of progress against diseases like polio, where the consequences of lower coverage can be severe and long-lasting. Policymakers and clinicians now face a fragmented landscape in which federal, state and professional guidance diverge, complicating both clinical practice and public-health planning.
Going forward, the most immediate priorities are clear: monitor coverage data closely, harmonize guidance where possible to reduce confusion, and communicate plainly to parents and clinicians about the continued risks posed by polio and other vaccine-preventable diseases. Absent clearer consensus and stronger uptake, the potential for localized outbreaks—and the human cost that would follow—remains a credible concern.